Genentech Continues Pipeline Push After Rituxan Fizzles In PPMS
Executive Summary
The failure of Genentech's Rituxan in a Phase II/III trial in primary progressive multiple sclerosis adds weight to the idea that B cells do not play a role in the disease and may cast doubt on rituximab's potential in lupus
You may also be interested in...
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
Next For Genentech: Tackling Neuroscience And Infectious Disease
Having built a heritage on the discovery of breakthrough medications in oncology, immunology and tissue growth and repair, Genentech is now turning its sights to tackling diseases in two new therapeutic areas: neuroscience and infectious disease